Department of Biotechnological and Applied Clinical Sciences (DISCAB), University of L'Aquila, 67100 L'Aquila, Italy; Centre for Cell Signalling and Inflammation, Department of Medicine, Imperial College London, London W12 0NN, UK.
Department of Biotechnological and Applied Clinical Sciences (DISCAB), University of L'Aquila, 67100 L'Aquila, Italy.
Semin Cell Dev Biol. 2018 Jun;78:51-61. doi: 10.1016/j.semcdb.2017.08.004. Epub 2017 Aug 2.
Tumour promoting inflammation is widely recognized as a hallmark of cancer. The source of this chronic inflammation in cancer has been ascribed to the progressive activation over time of immune cells, mostly of the innate arm of the immune system. However, recent evidence has shown that chronic inflammation may also derive, at least in part, from senescent cells. Hence, due to the prominent role of inflammation in cancer, the cancer secretome definition includes all the secretory factors ensuing from the crosstalk between the cancer cell and the tumour microenvironment. The mechanistic basis underlying the paracrine signalling between the cancer cell and the surrounding tumour microenvironment in malignancy have been widely investigated by using in vivo models of cancers, thus identifying the NF-κB transcription factor as the molecular hub linking inflammation and cancer. In this review, we highlight the roles of NF-κB in regulating the inflammation-derived secretome emanating from immune and senescent cells, with a special focus on the bright and the dark sides of their pro-inflammatory signalling on tumorigenesis.
肿瘤促进炎症被广泛认为是癌症的一个标志。癌症中这种慢性炎症的来源归因于免疫细胞的逐渐激活,主要是免疫系统的先天免疫部分。然而,最近的证据表明,慢性炎症也可能至少部分来源于衰老细胞。因此,由于炎症在癌症中的突出作用,癌症分泌组的定义包括了癌细胞与肿瘤微环境之间相互作用产生的所有分泌因子。通过使用癌症的体内模型,广泛研究了癌细胞与周围肿瘤微环境之间旁分泌信号的机制基础,从而确定 NF-κB 转录因子是连接炎症和癌症的分子枢纽。在这篇综述中,我们强调了 NF-κB 在调节源自免疫细胞和衰老细胞的炎症衍生分泌组中的作用,特别关注它们在肿瘤发生中的促炎信号的光明面和黑暗面。
Semin Cell Dev Biol. 2017-8-2
Nat Rev Immunol. 2018-1-22
Trends Cell Biol. 2015-11-9
Trends Biochem Sci. 2005-1
Biochim Biophys Acta. 2013-11
Nat Rev Immunol. 2017-9
MedComm (2020). 2025-1-5
Front Pharmacol. 2024-5-10
Cancer Genomics Proteomics. 2023